Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T04507
(Former ID: TTDR00806)
|
|||||
Target Name |
Presynaptic density protein 95 (DLG4)
|
|||||
Synonyms |
Synapse-associated protein 90; SAP90; SAP-90; Postsynaptic density-95; Postsynaptic density protein 95; PSD95; PSD-95; Disks large homolog 4; Discs, large homolog 4
Click to Show/Hide
|
|||||
Gene Name |
DLG4
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Cerebral ischaemia [ICD-11: 8B1Z] | |||||
2 | Ischaemic/haemorrhagic stroke [ICD-11: 8B20] | |||||
Function |
Required for synaptic plasticity associated with NMDA receptor signaling. Overexpression or depletion of DLG4 changes the ratio of excitatory to inhibitory synapses in hippocampal neurons. May reduce the amplitude of ASIC3 acid-evoked currents by retaining the channel intracellularly. May regulate the intracellular trafficking of ADR1B. Also regulates AMPA-type glutamate receptor (AMPAR) immobilization at postsynaptic density keeping the channels in an activated state in the presence of glutamate and preventing synaptic depression. Interacts with the cytoplasmic tail of NMDA receptor subunits and shaker-type potassium channels.
Click to Show/Hide
|
|||||
BioChemical Class |
Ezrin/radixin/moesin-binding phosphoprotein 50
|
|||||
UniProt ID | ||||||
Sequence |
MDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGE
MEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFV NEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGN QHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVY LKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKD LLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQIL SVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGT ASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDS ETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIIL GPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIE AGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLE INKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPA RERL Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T27ZM7 |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | Tat-NR2B9c | Drug Info | Phase 3 | Cerebrovascular ischaemia | [1], [2], [3] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 18 Inhibitor drugs | + | ||||
1 | Tat-NR2B9c | Drug Info | [1], [2], [3] | |||
2 | 2-Methyl-2,4-Pentanediol | Drug Info | [4] | |||
3 | FETAV | Drug Info | [5] | |||
4 | Guanosine-5'-Monophosphate | Drug Info | [4] | |||
5 | KSG-YEKLSSIESDV | Drug Info | [5] | |||
6 | N-(3,4-Dichlorophenyl)propyl-ETAV | Drug Info | [5] | |||
7 | N-(3,4-Difluorophenyl)propyl-ETAV | Drug Info | [5] | |||
8 | N-(Naphthalene-2-yl)ethyl-ETAV | Drug Info | [5] | |||
9 | N-Benzyl-ETAV | Drug Info | [5] | |||
10 | N-Butyl-ETAV | Drug Info | [5] | |||
11 | N-Cyclohexylethyl-ETAV | Drug Info | [5] | |||
12 | N-Cyclohexylmethyl-ETAV | Drug Info | [5] | |||
13 | N-Ethyl-ETAV | Drug Info | [5] | |||
14 | N-Methyl-ETAV | Drug Info | [5] | |||
15 | N-Phenylethyl-ETAV | Drug Info | [5] | |||
16 | N-Phenylpropyl-ETAV | Drug Info | [5] | |||
17 | N-Propyl-ETAV | Drug Info | [5] | |||
18 | YGRKKRRQRRR-KLSSIESDV | Drug Info | [5] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Glutathione | Ligand Info | |||||
Structure Description | Crystal structure of PDZ1-2 from PSD-95 | PDB:6SPV | ||||
Method | X-ray diffraction | Resolution | 2.04 Å | Mutation | No | [6] |
PDB Sequence |
EGEMEYEEIT
67 LERGNSGLGF77 SIAGGTDNPH87 IGDDPSIFIT97 KIIPGGAAAQ107 DGRLRVNDSI 117 LFVNEVDVRE127 VTHSAAVEAL137 KEAGSIVRLY147 VMRRKPPAEK157 VMEIKLIKGP 167 KGLGFSIAGG177 VGNQHIPGDN187 SIYVTKIIEG197 GAAHKDGRLQ207 IGDKILAVNS 217 VGLEDVMHED227 AVAALKNTYD237 VVYLKVAKP
|
|||||
|
||||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Hippo signaling pathway | hsa04390 | Affiliated Target |
|
Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
Glutamatergic synapse | hsa04724 | Affiliated Target |
|
Class: Organismal Systems => Nervous system | Pathway Hierarchy |
Degree | 69 | Degree centrality | 7.41E-03 | Betweenness centrality | 1.40E-02 |
---|---|---|---|---|---|
Closeness centrality | 2.51E-01 | Radiality | 1.44E+01 | Clustering coefficient | 2.77E-02 |
Neighborhood connectivity | 1.44E+01 | Topological coefficient | 2.42E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-interacting Proteins |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 4 KEGG Pathways | + | ||||
1 | Hippo signaling pathway | |||||
2 | Glutamatergic synapse | |||||
3 | Huntington's disease | |||||
4 | Cocaine addiction | |||||
Panther Pathway | [+] 1 Panther Pathways | + | ||||
1 | Huntington disease | |||||
PID Pathway | [+] 1 PID Pathways | + | ||||
1 | ErbB4 signaling events | |||||
Reactome | [+] 6 Reactome Pathways | + | ||||
1 | Trafficking of AMPA receptors | |||||
2 | Unblocking of NMDA receptor, glutamate binding and activation | |||||
3 | CREB phosphorylation through the activation of CaMKII | |||||
4 | Ras activation uopn Ca2+ infux through NMDA receptor | |||||
5 | RHO GTPases activate CIT | |||||
6 | RAF/MAP kinase cascade | |||||
WikiPathways | [+] 2 WikiPathways | + | ||||
1 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
2 | L1CAM interactions |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. | |||||
REF 2 | Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995 Sep 22;269(5231):1737-40. | |||||
REF 3 | Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999 Jun 11;284(5421):1845-8. | |||||
REF 4 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 5 | Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. | |||||
REF 6 | The Dual PDZ Domain from Postsynaptic Density Protein 95 Forms a Scaffold with Peptide Ligand. Biophys J. 2020 Aug 4;119(3):667-689. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.